HEALTHCARE STRATEGIC MARKET ASSESSMENT UNCOVERS SUBSTANTIAL POTENTIAL FOR OB-GYN STARTUP CHALLENGE Women in the United States suffering from benign uterine tumors usually face two choices: cope with severe pain and heavy menstruation or undergo major surgery — typically a hysterectomy to remove the entire uterus. Neither option is desirable, especially for women interested in bearing children. However, a women’s health startup recently developed a breakthrough technology to treat uterine fibroids noninvasively. While the leadership team believed it had a game-changing technology and a strong understanding of its clinical potential, they wanted third-party validation of the therapy’s true market potential prior to launching it or negotiating with possible acquirers. SOLUTION To ev

Join for free to read